Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | G6PD | P11413 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9464929 | 0.81 | NOS1 (0.38) | NOS1FBP1FDPSKDM4EALDH1A1 | |
| SCHEMBL1824256 | 0.74 | NFKB1 (0.33) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL28704502 | 0.72 | NFKB1 (0.32) | — | |
| SCHEMBL15940234 | 0.65 | — | — | |
| SCHEMBL5967475 | 0.65 | SMPD3 (0.32) | — | |
| SCHEMBL4729301 | 0.65 | — | — | |
| SCHEMBL2067806 | 0.64 | ADORA2A (0.33) | — | |
| SCHEMBL8427375 | 0.64 | CYP2A6 (0.31) | FBP1KDM4EALDH1A1 | |
| SCHEMBL6071914 | 0.63 | CYP19A1 (0.31) | — | |
| SCHEMBL4296374 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| EP-3600302-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | United States Government as Represented by The Department of Veterans Affairs (US) | 2020-02-05 | — | — | EP | claimed |
| US-20190231778-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-08-01 | — | — | US | claimed |
| WO-2018183762-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2018-10-04 | — | — | WO | claimed |
| US-20130274386-A1 | DRIER COMPOSITION AND USE THEREOF | PPG EUROPE BV (NL) | 2013-10-17 | — | — | US | claimed |
| EP-2342200-B1 | Compounds which selectively modulate the cb2 receptor | BOEHRINGER INGELHEIM INT (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2013001372-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ACTIVATION OF REGULATORY T CELLS | UNIVERSITY OF OSLO (NO) | 2013-01-03 | — | — | WO | claimed |
| EP-1786801-B1 | 2-ARYLCARBAMOYL-INDOLES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-03-10 | — | — | EP | claimed |
| EP-1819721-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | Plant Bioscience Limited (GB) | 2007-08-22 | — | — | EP | claimed |
| WO-2006054102-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | PLANT BIOSCIENCE LIMITED (GB) | 2006-05-26 | — | — | WO | claimed |
| JP-4247072-A | — | — | None | — | — | JP | disclosed |
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| WO-2006054102-A1 | MICROCIN B17 ANALOGS AND METHODS FOR THEIR PREPARATION AND USE | PLANT BIOSCIENCE LIMITED (GB) | 2006-05-26 | — | — | WO | disclosed |
| EP-1560827-A1 | ANTI-INFECTIVE AGENTS | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041818-A1 | ANTI-INFECTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-05-21 | — | — | WO | disclosed |
| US-5246914-A | Fungicides and plant growth regulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-21 | — | — | US | disclosed |
| JP-H04247072-A | SULFONAMIDE, HERBICIDE AND PLANT GROWTH REGULATOR CONTAINING THE SAME | BASF AG | 1992-09-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CCR10, SLC11A2, MSR1 | NOS1 1532/4885FBP1 3150/4885FDPS 2924/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | NOS1 4618/4885FBP1 517/4885FDPS 1094/4885 |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MOK, TTK, MAPK4 | NOS1 3282/4885FBP1 1901/4885FDPS 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.